Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

577
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
577
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

875
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
875
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

827
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
827
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
263
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

888
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
888

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiseizure Medications and Bone Health.

Neurology and therapy·2025
Same author

Cross-cultural insights into non-communicable disease perceptions: a five-nation survey.

BMJ public health·2025
Same author

Progression of obesity and abdominal obesity after the COVID-19 pandemic in Colombia: a comparison of two cross-sectional population-based studies.

BMJ public health·2025
Same author

Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2024
Same author

MDRD is the eGFR equation most strongly associated with 4-year mortality among patients with diabetes in Colombia.

BMJ open diabetes research & care·2023
Same author

Consumption of Sugary Drinks among Urban Adults in Colombia: Association with Sociodemographic Factors and Body Adiposity.

International journal of environmental research and public health·2023
Same journal

Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Novel Clinical and Pre-clinical Obesity Estimates in Older Indian Adults: Insights from a Nationally Representative Dataset.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same journal

Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 13, 2025

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

7.9K

Fenofibrate and Diabetic Retinopathy.

A Parra-Pineda1, S Lizarazo-Bocanegra1, L F Villalba-Montero1

  • 1School of Medicine, Universidad de los Andes, Carrera 7 No 116-05, Of. 413, Bogotá, Colombia.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|July 30, 2025
PubMed
Summary
This summary is machine-generated.

Fenofibrate, a PPAR-alpha activator, is the first medication proven to slow diabetic retinopathy (DR) progression. This treatment offers a novel approach to managing DR, independent of blood sugar control.

Keywords:
ComplicationsDiabetesFenofibrateMacular edemaPPARRetinopathy

More Related Videos

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

13.5K
Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

4.7K

Related Experiment Videos

Last Updated: Sep 13, 2025

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

7.9K
Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

13.5K
Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

4.7K

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic retinopathy (DR) is a leading cause of blindness affecting over 125 million people globally.
  • DR pathogenesis involves complex pathways, often worsened by hyperglycemia, but not solely caused by it.
  • Fibrates, like fenofibrate, target peroxisome proliferator-activated receptor alpha (PPAR-alpha), which is present in the retina.

Purpose of the Study:

  • To evaluate the efficacy of fenofibrate in managing diabetic retinopathy.
  • To determine if PPAR-alpha activation by fenofibrate can mitigate DR-related cellular damage.
  • To assess fenofibrate's impact on DR progression independent of glycemic control.

Main Methods:

  • Review of secondary analyses from cardiovascular outcome trials involving fenofibrate.
  • Analysis of data from the dedicated randomized LENS (Lowering Events in Non-Proliferative Retinopathy) study.
  • Investigation of PPAR-alpha activation's effects on retinal inflammation, oxidative stress, and vascular permeability in preclinical models.

Main Results:

  • Preclinical models show PPAR-alpha activation by fibrates improves DR-related cellular processes.
  • Secondary analyses indicated fenofibrate benefits DR appearance and severity.
  • The LENS study demonstrated that early fenofibrate use significantly reduces the risk of DR progression.

Conclusions:

  • Fenofibrate is the first agent proven to specifically delay diabetic retinopathy progression.
  • The therapeutic effect of fenofibrate on DR is independent of glycemic control.
  • Further research is warranted to explore fenofibrate's potential benefits for other diabetic microvascular complications.